Intraventricular injection of eravacycline in the treatment of carbapenem-resistant Acinetobacter baumannii meningitis: a case report

[1] Jesudason T., WHO publishes updated list of bacterial priority pathogens, Lancet Microbe, 5, (2024)

[2] Tamma PD, Heil EL, Justo JA, Et al., Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections, Clin Infect Dis, 2024

[3] Hu Y, Li D, Zhang G, Et al., Intraventricular or intrathecal polymyxin B for treatment of post-neurosurgical intracranial infection caused by carbapenem-resistant gram-negative bacteria: a 8-year retrospective study, Eur J Clin Microbiol Infect Dis, 43, pp. 875-884, (2024)

[4] Zhong L, Shi XZ, Su L, Et al., Sequential intraventricular injection of tigecycline and polymyxin B in the treatment of intracranial Acinetobacter baumannii infection after trauma: a case report and review of the literature, Mil Med Res, 7, (2020)

[5] Livermore DM, Mushtaq S, Warner M, Et al., In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii, Antimicrob Agents Chemother, 60, pp. 3840-3844, (2016)

[6] Morrissey I, Olesky M, Hawser S, Et al., In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017, Antimicrob Agents Chemother, 64, pp. e01699-19, (2020)

[7] Seifert H, Stefanik D, Sutcliffe JA, Et al., In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii, Int J Antimicrob Agents, 51, pp. 62-64, (2018)

[8] Alosaimy S, Morrisette T, Lagnf AM, Et al., Clinical outcomes of eravacycline in patients treated predominately for carbapenem-resistant Acinetobacter baumannii, Microbiol Spectr, 10, (2022)

[1] Jesudason T., WHO publishes updated list of bacterial priority pathogens, Lancet Microbe, 5, (2024)

[2] Tamma PD, Heil EL, Justo JA, Et al., Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections, Clin Infect Dis, 2024

[3] Hu Y, Li D, Zhang G, Et al., Intraventricular or intrathecal polymyxin B for treatment of post-neurosurgical intracranial infection caused by carbapenem-resistant gram-negative bacteria: a 8-year retrospective study, Eur J Clin Microbiol Infect Dis, 43, pp. 875-884, (2024)

[4] Zhong L, Shi XZ, Su L, Et al., Sequential intraventricular injection of tigecycline and polymyxin B in the treatment of intracranial Acinetobacter baumannii infection after trauma: a case report and review of the literature, Mil Med Res, 7, (2020)

[5] Livermore DM, Mushtaq S, Warner M, Et al., In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii, Antimicrob Agents Chemother, 60, pp. 3840-3844, (2016)

[6] Morrissey I, Olesky M, Hawser S, Et al., In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017, Antimicrob Agents Chemother, 64, pp. e01699-19, (2020)

[7] Seifert H, Stefanik D, Sutcliffe JA, Et al., In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii, Int J Antimicrob Agents, 51, pp. 62-64, (2018)

[8] Alosaimy S, Morrisette T, Lagnf AM, Et al., Clinical outcomes of eravacycline in patients treated predominately for carbapenem-resistant Acinetobacter baumannii, Microbiol Spectr, 10, (2022)